Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesAnuja Chatterjee, Matthew S. Davids, Sheila Shapouri et al.|Journal of Managed Care & Specialty Pharmacy|2021Cited by 20
Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United StatesMatthew S. Davids, Michael Hallek, Anuja Chatterjee et al.|Blood|2019Cited by 11
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapyMartina Paoletti, M. Jootun, Rosita van den Puttelaar et al.|Journal of Medical Economics|2025Cited by 1